Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 316

1.
3.

Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.

Jirapinyo M, Theppisai U, Manonai J, Suchartwatnachai C, Jorgensen LN.

Acta Obstet Gynecol Scand. 2003 Sep;82(9):857-66.

PMID:
12911449
4.

A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function.

Teede HJ, Liang YL, Kotsopoulos D, Zoungas S, Cravent R, McGrath BP.

Clin Endocrinol (Oxf). 2001 Nov;55(5):673-82.

PMID:
11894980
5.

Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers.

Stevenson JC, Oladipo A, Manassiev N, Whitehead MI, Guilford S, Proudler AJ.

Br J Haematol. 2004 Mar;124(6):802-8.

PMID:
15009069
6.

Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.

Davidson MH, Maki KC, Marx P, Maki AC, Cyrowski MS, Nanavati N, Arce JC.

Arch Intern Med. 2000 Nov 27;160(21):3315-25.

PMID:
11088095
7.

Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.

Kimmerle R, Heinemann L, Heise T, Bender R, Weyer C, Hirschberger S, Berger M.

Menopause. 1999 Spring;6(1):36-42.

PMID:
10100178
8.

Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.

Davis SR, Goldstat R, Newman A, Berry K, Burger HG, Meredith I, Koch K.

Climacteric. 2002 Dec;5(4):341-50.

PMID:
12626213
9.
10.

Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens.

Fernandes EO, Moraes RS, Ferlin EL, Wender MC, Ribeiro JP.

Pacing Clin Electrophysiol. 2005 Jan;28 Suppl 1:S172-7.

PMID:
15683490
11.

Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17beta-estradiol and norethisterone acetate.

Samsioe G, Li C, Borgfeldt C, Wilawan K, Aberg A, Larsen S.

Menopause. 2002 Sep-Oct;9(5):335-42.

PMID:
12218722
12.
13.
14.
15.

Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women.

Rosano GM, Webb CM, Chierchia S, Morgani GL, Gabraele M, Sarrel PM, de Ziegler D, Collins P.

J Am Coll Cardiol. 2000 Dec;36(7):2154-9.

18.

Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women.

Saitta A, Altavilla D, Cucinotta D, Morabito N, Frisina N, Corrado F, D'Anna R, Lasco A, Squadrito G, Gaudio A, Cancellieri F, Arcoraci V, Squadrito F.

Arterioscler Thromb Vasc Biol. 2001 Sep;21(9):1512-9.

PMID:
11557681
19.

The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms.

Speroff L, Symons J, Kempfert N, Rowan J; femhrt Study Investigators.

Menopause. 2000 Nov-Dec;7(6):383-90.

PMID:
11127760
20.

Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris.

Knuuti J, Kalliokoski R, Janatuinen T, Hannukainen J, Kalliokoski KK, Koskenvuo J, Lundt S.

Am J Cardiol. 2007 Jun 15;99(12):1648-52. Epub 2007 Apr 27.

PMID:
17560868

Supplemental Content

Support Center